Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins

Author(s): Qun Zhou*

Journal Name: Current Drug Targets

Volume 19 , Issue 13 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Glycan-binding proteins are widely distributed in human and play an essential role in biological processes. Their involvements in inflammatory and immune responses make it increasingly likely that the glycan-binding proteins may represent valuable therapeutic targets.

Objective: The current review aims to provide information on recent advancements in clinical developments of antibodies against glycan-binding proteins as potential targets.

Results and Conclusion: There are several therapeutic antibodies being developed targeting glycanbinding proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies have provided great promises in therapeutic targeting of more glycan-binding proteins for treating multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies.

Keywords: Glycan-binding proteins, lectins, antibodies, clinical development, inflammation, autoimmune diseases, hematological malignancies.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 08 March, 2018
Page: [1491 - 1497]
Pages: 7
DOI: 10.2174/1389450119666180308144313
Price: $65

Article Metrics

PDF: 35